Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1-Year and 2-Year Clinical, Radiologic, and Physical Function Findings-Reference-Cited by-同舟云学术

Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1-Year and 2-Year Clinical, Radiologic, and Physical Function Findings

Published:2013-11 Issue:11 Volume:65 Page:1732-1742
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Emery Paul¹,Fleischmann Roy M.²,Doyle Mittie K.³,Strusberg Ingrid⁴,Durez Patrick⁵,Nash Peter⁶,Amante Eric⁷,Churchill Melvin⁸,Park Won⁹,Pons-Estel Bernardo¹⁰,Xu Weichun³,Xu Stephen³,Wu Zhong³,Hsia Elizabeth C.¹¹

Affiliation:

1. Leeds Institute of Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; Leeds UK

2. University of Texas/Southwest Medical Center; Dallas

3. Janssen Research & Development; LLC, Spring House Pennsylvania

4. Instituto Reumatológico Strusberg; Cordoba Argentina

5. Cliniques Universitaires Saint-Luc et Institut de Recherche Experimentale et Clinique and Université Catholique de Louvain; Brussels Belgium

6. University of Queensland, Sunshine Coast; Queensland Australia

7. University of Philippines and Philippine General Hospital; Manila Philippines

8. Arthritis Center of Nebraska; Lincoln

9. Inha University Hospital; Incheon South Korea

10. Sanatorio Parque; Santa Fe Argentina

11. Janssen Research & Development, LLC, Spring House, and University of Pennsylvania, School of Medicine; Philadelphia

Publisher

Wiley